Abbott Vascular's Xience V Drug-Eluting Stent Experiences Rapid Adoption During Its Q1 2010 Launch, According To Millennium Research Group

WALTHAM, Mass., May 5 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, when Abbott Vascular's Xience V and Boston Scientific's Promus entered the Japanese drug-eluting stent market in Q1 2010, both companies picked up share from competitors Medtronic and Cordis.

In its peak sales month, Xience V was used in over 50% of drug-eluting stent procedures, and averaged a unit share of just less than 40% for the first quarter 2010.  Meanwhile, Promus captured approximately one-third of Xience V's unit share during the same time period, despite the fact that the devices are identical and were launched simultaneously.

When Boston Scientific acquired Guidant in 2006 they divested Guidant's cardiovascular businesses to Abbott Vascular; however, under the agreement Boston Scientific can sell a restricted quantity of Guidant's drug-eluting stent, marketed under the Promus brand, for a limited time.  In Japan, this agreement ends in June 2012.

"Xience V is out-performing Promus almost 3 to 1 in Japan," says Bina Mistry, Senior Analyst at MRG. "Both devices are identical in clinical safety and efficacy and prices do not vary drastically between the brands. There are two reasons for this trend. First, because most clinical trials studying this device are predominantly using Xience V, this stent is building up better brand recognition, and in some cases, physicians may even be unaware that the Xience V and Promus are the same device; this phenomenon has occurred in other regions around the world. Second, Abbott Vascular has a breadth of successful coronary products, including bare-metal stent and angioplasty balloons, and a strong company image in Japan; physicians who prefer the Abbott name may adopt Xience V over Promus."      

MRG's Japanese Interventional Cardiology Marketrack™ gathers data from 110 catheterization labs throughout Japan on a monthly basis. Product categories covered include drug-eluting coronary stents, bare-metal coronary stents, percutaneous transluminal coronary angioplasty (PTCA) balloons, guidewires, guiding catheters, diagnostic catheters, embolic protection devices, intravascular ultrasound (IVUS) catheters, introducer sheaths, atherectomy devices, thrombectomy devices, inflation devices, optical coherence tomography (OCT) devices, and vascular closure devices. MRG also gathers data from the US, Europe, Asia Pacific, Latin America, and the Middle East. Marketrack subscribers receive thousands of data points, including usage (units, average selling prices, and revenues), procedures, competitor shares, and brand-level information.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer behavior tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Millennium Research Group

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED